There is growing awareness of the overlap between oncologic and cardiovascular (CV) diseases, including a wide range of CV effects of anticancer therapies. As novel anticancer therapeutics become available and cancer survival outcomes improve, the CV implications of cancer therapy become increasingly important. In addition to outlining the CV effects of commonly used cancer therapies and their consequences for long-term survivorship, this review highlights the recent efforts to improve the risk prediction and prevention of CV toxicity through the evaluation of sensitive measures for early toxicity detection and the implementation of cardioprotective strategies.


Article metrics loading...

Loading full text...

Full text loading...


Literature Cited

  1. Siegel RL, Miller KD, Jemal A. 1.  2016. Cancer statistics, 2016.. CA Cancer J. Clin. 66:7–30 [Google Scholar]
  2. Ewer MS, Ewer SM. 2.  2015. Cardiotoxicity of anticancer treatments. Nat. Rev. Cardiol. 12:547–58 [Google Scholar]
  3. Koene RJ, Prizment AE, Blaes A. 3.  et al. 2016. Shared risk factors in cardiovascular disease and cancer. Circulation 133:1104–14 [Google Scholar]
  4. Arts–de Jong M, Maas AH, Massuger LF. 4.  et al. 2014. BRCA1/2 mutation carriers are potentially at higher cardiovascular risk. Crit. Rev. Oncol. Hematol. 91:159–71 [Google Scholar]
  5. Doyle JJ, Neugut AI, Jacobson JS. 5.  et al. 2005. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J. Clin. Oncol. 23:8597–605 [Google Scholar]
  6. Patnaik JL, Byers T, DiGuiseppi C. 6.  et al. 2011. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 13:64 [Google Scholar]
  7. Van Den Belt–Dusebout AW De Wit R, Gietema JA. 7.  et al. 2007. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 25:4370–78 [Google Scholar]
  8. Armenian SH, Lacchetti C, Barac A. 8.  et al. 2017. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 35:893–911 [Google Scholar]
  9. Gewirtz DA. 9.  1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57:727–41 [Google Scholar]
  10. Doroshow JH. 10.  1983. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43:460–72 [Google Scholar]
  11. Zhang S, Liu X, Bawa-Khalfe T. 11.  et al. 2012. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18:1639–42 [Google Scholar]
  12. Lefrak EA, Pitha J, Rosenheim S. 12.  et al. 1973. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302–14 [Google Scholar]
  13. Swain SM, Whaley FS, Ewer MS. 13.  2003. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–79 [Google Scholar]
  14. Harbeck N, Ewer MS, De Laurentiis M. 14.  et al. 2011. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann. Oncol. 22:1250–58 [Google Scholar]
  15. Curigliano G, Cardinale D, Dent S. 15.  et al. 2016. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J. Clin. 66:309–25 [Google Scholar]
  16. von Hoff DD, Layard MW, Basa P. 16.  et al. 1979. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91:710–17 [Google Scholar]
  17. Ewer MS, Ewer SM. 17.  2010. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat. Rev. Cardiol. 7:564–75 [Google Scholar]
  18. Narayan HK, Finkelman B, French B. 18.  et al. 2017. Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation 135:1397–412 [Google Scholar]
  19. Swain SM, Whaley FS, Gerber MC. 19.  et al. 1997. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 15:1318–32 [Google Scholar]
  20. Lipshultz SE, Scully RE, Lipsitz SR. 20.  et al. 2010. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950–61 [Google Scholar]
  21. van Dalen EC, Caron HN, Dickinson HO. 21.  et al. 2011. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. 6:CD003917 [Google Scholar]
  22. Hensley ML, Hagerty KL, Kewalramani T. 22.  et al. 2009. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 27:127–45 [Google Scholar]
  23. Casper ES, Gaynor JJ, Hajdu SI. 23.  et al. 1991. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 68:1221–29 [Google Scholar]
  24. Lipshultz SE, Miller TL, Lipsitz SR. 24.  et al. 2012. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics 130:1003–11 [Google Scholar]
  25. Yamaguchi N, Fujii T, Aoi S. 25.  et al. 2015. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Eur. J. Cancer 51:2314–20 [Google Scholar]
  26. Slamon DJ, Eiermann W, Robert NJ. 26.  et al. 2015. Ten-year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-positive early breast cancer patients. Presented at San Antonio Breast Cancer Symp San Antonio, TX: Dec. 11, Abstr. S5–04
  27. Crone SA, Zhao Y, Fan L. 27.  et al. 2002. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8:459–65 [Google Scholar]
  28. Hahn VS, Lenihan DJ, Ky B. 28.  2014. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J. Am. Heart Assoc. 3:e000665 [Google Scholar]
  29. Slamon DJ, Leyland-Jones B, Shak S. 29.  et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783–92 [Google Scholar]
  30. Ewer MS, Vooletich MT, Durand J. 30.  et al. 2005. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23:7820–26 [Google Scholar]
  31. Perez EA, Romond EH, Suman VJ. 31.  et al. 2011. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol. 29:3366–73 [Google Scholar]
  32. Slamon D, Eiermann W, Robert N. 32.  et al. 2011. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365:1273–83 [Google Scholar]
  33. Romond EH, Jeong JH, Rastogi P. 33.  et al. 2012. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30:3792–99 [Google Scholar]
  34. De Azambuja E, Procter MJ, Van Veldhuisen DJ. 34.  et al. 2014. Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1–01). J. Clin. Oncol. 32:2159–65 [Google Scholar]
  35. de Korte MA, de Vries EGE, Lub–de Hooge MN. 35.  et al. 2007. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur. J. Cancer 43:2046–51 [Google Scholar]
  36. Dang C, Guo H, Najita J. 36.  et al. 2016. Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer. JAMA Oncol 2:29–36 [Google Scholar]
  37. Foglietta J, Inno A, de Iuliis F. 37.  et al. 2017. Cardiotoxicity of aromatase inhibitors in breast cancer patients. Clin. Breast Cancer 17:11–17 [Google Scholar]
  38. Love RR, Wiebe DA, Feyzi JM. 38.  et al. 1994. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl. Cancer Inst. 86:1534–39 [Google Scholar]
  39. Khosrow-Khavar F, Filion K, Al-Qurashi S. 39.  et al. 2017. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann. Oncol 28:487–95 [Google Scholar]
  40. Buzdar A, Howell A, Cuzick J. 40.  et al. 2006. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633–43 [Google Scholar]
  41. Coates AS, Keshaviah A, Thürlimann B. 41.  et al. 2007. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J. Clin. Oncol. 25:486–92 [Google Scholar]
  42. Burstein HJ, Temin S, Anderson H. 42.  et al. 2014. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J. Clin. Oncol. 32:2255–69 [Google Scholar]
  43. Riihimäki M, Thomsen H, Brandt A. 43.  et al. 2011. What do prostate cancer patients die of?. Oncologist 16:175–81 [Google Scholar]
  44. Epstein MM, Edgren G, Rider JR. 44.  et al. 2012. Temporal trends in cause of death among Swedish and US men with prostate cancer. J. Natl. Cancer Inst. 104:1335–42 [Google Scholar]
  45. Smith JC, Bennett S, Evans LM. 45.  et al. 2001. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J. Clin. Endocrinol. Metab. 86:4261–67 [Google Scholar]
  46. Lakka H, Laaksonen DE, Lakka TA. 46.  et al. 2002. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–16 [Google Scholar]
  47. Keating NL, O'Malley AJ, Smith MR. 47.  2006. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24:4448–56 [Google Scholar]
  48. D'Amico AV, Denham JW, Crook J. 48.  et al. 2007. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol. 25:2420–25 [Google Scholar]
  49. Nguyen PL, Alibhai SMH, Basaria S. 49.  et al. 2015. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur. Urol. 67:825–36 [Google Scholar]
  50. Nguyen PL, Je Y, Schutz FAB. 50.  et al. 2011. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306:2359–66 [Google Scholar]
  51. Bhatia N, Santos M, Jones LW. 51.  et al. 2016. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation 133:537–41 [Google Scholar]
  52. D'Amico AV, Chen M, Renshaw A. 52.  et al. 2015. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 314:1291–93 [Google Scholar]
  53. Jaworski C, Mariani JA, Wheeler G. 53.  et al. 2013. Cardiac complications of thoracic irradiation. J. Am. Coll. Cardiol. 61:2319–28 [Google Scholar]
  54. Gaya AM, Ashford RFU. 54.  2005. Cardiac complications of radiation therapy. Clin. Oncol. 17:153–59 [Google Scholar]
  55. Hancock SL, Hoppe RT, Tucker MA. 55.  1993. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270:1949–55 [Google Scholar]
  56. Darby SC, Ewertz M, McGale P. 56.  et al. 2013. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368:987–98 [Google Scholar]
  57. Hull MC, Morris CG, Pepine CJ. 57.  et al. 2003. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290:2831–37 [Google Scholar]
  58. Van Nimwegen FA, Schaapveld M, Cutter DJ. 58.  et al. 2016. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J. Clin. Oncol. 34:235–43 [Google Scholar]
  59. Hoppe BS, Flampouri S, Su Z. 59.  et al. 2012. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 84:449–55 [Google Scholar]
  60. Paumier A, Ghalibafian M, Gilmore J. 60.  et al. 2012. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 82:1522–27 [Google Scholar]
  61. Engert A, Plütschow A, Eich HT. 61.  et al. 2010. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N. Engl. J. Med. 363:640–52 [Google Scholar]
  62. Schmidinger M, Zielinski CC, Vogl UM. 62.  et al. 2008. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26:5204–12 [Google Scholar]
  63. Chu TF, Rupnick MA, Kerkela R. 63.  et al. 2007. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011–19 [Google Scholar]
  64. Rainer PP, Doleschal B, Kirk JA. 64.  et al. 2012. Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes. Br. J. Urol. Int. 110:1455–62 [Google Scholar]
  65. Force T, Krause DS, Van Etten RA. 65.  2007. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer. 7:332–44 [Google Scholar]
  66. Hamnvik OR, Choueiri TK, Turchin A. 66.  et al. 2015. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 121:311–19 [Google Scholar]
  67. Telli ML, Witteles RM, Fisher GA. 67.  et al. 2008. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann. Oncol. 19:1613–18 [Google Scholar]
  68. Hall PS, Harshman LC, Srinivas S. 68.  et al. 2013. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 1:72–78 [Google Scholar]
  69. Narayan V, Keefe S, Haas N. 69.  et al. 2017. Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 23:3601–9 [Google Scholar]
  70. Copur MS, Obermiller A. 70.  2011. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin. Colorectal Cancer 10:151–56 [Google Scholar]
  71. Narayan V, Haas NB. 71.  2016. Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. Int. J. Nephrol. Renovascular Dis. 9:65–72 [Google Scholar]
  72. Rini BI, Schiller JH, Fruehauf JP. 72.  et al. 2011. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin. Cancer Res. 17:3841–49 [Google Scholar]
  73. Michaelson MD, Stadler WM. 73.  2013. Predictive markers in advanced renal cell carcinoma. Semin. Oncol. 40:459–64 [Google Scholar]
  74. Postow MA, Callahan MK, Wolchok JD. 74.  2015. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33:1974–82 [Google Scholar]
  75. Naidoo J, Page DB, Li BT. 75.  et al. 2015. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26:2375–91 [Google Scholar]
  76. Johnson DB, Balko JM, Compton ML. 76.  et al. 2016. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375:1749–55 [Google Scholar]
  77. Yancy CW, Jessup M, Bozkurt B. 77.  et al. 2013. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 128:1810–52 [Google Scholar]
  78. Cardinale D, Colombo A, Bacchiani G. 78.  et al. 2015. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981–88 [Google Scholar]
  79. Plana JC, Galderisi M, Barac A. 79.  et al. 2014. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 27:911–39 [Google Scholar]
  80. Ewer MS, Lenihan DJ. 80.  2008. Left ventricular ejection fraction and cardiotoxicity: Is our ear really to the ground?. J. Clin. Oncol. 26:1201–3 [Google Scholar]
  81. Thavendiranathan P, Poulin F, Lim K. 81.  et al. 2014. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J. Am. Coll. Cardiol. 63:2751–68 [Google Scholar]
  82. Narayan HK, French B, Khan AM. 82.  et al. 2016. Noninvasive measures of ventricular-arterial coupling and circumferential strain predict cancer therapeutics-related cardiac dysfunction. JACC Cardiovasc. Imaging. 9:1131–41 [Google Scholar]
  83. Yu AF, Ky B. 83.  2016. Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart 102:425–30 [Google Scholar]
  84. Cardinale D, Colombo A, Torrisi R. 84.  et al. 2010. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J. Clin. Oncol. 28:3910–16 [Google Scholar]
  85. Cardinale D, Sandri MT, Colombo A. 85.  et al. 2004. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749–54 [Google Scholar]
  86. Meinardi MT, Van Veldhuisen DJ Gietema JA. 86.  et al. 2001. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J. Clin. Oncol. 19:2746–53 [Google Scholar]
  87. Daugaard G, Lassen U, Bie P. 87.  et al. 2005. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur. J. Heart Fail. 7:87–93 [Google Scholar]
  88. Gulati G, Heck SL, Ree AH. 88.  et al. 2016. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur. Heart J. 37:1671–80 [Google Scholar]
  89. Pituskin E, Mackey JR, Koshman S. 89.  et al. 2017. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J. Clin. Oncol. 35:870–77 [Google Scholar]
  90. Boekhout A, Gietema J, Kerklaan B. 90.  et al. 2016. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol 2:1030–37 [Google Scholar]
  91. Jones LW, Habel LA, Weltzien E. 91.  et al. 2016. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J. Clin. Oncol. 34:2743–49 [Google Scholar]
  92. De Moor JS, Mariotto AB, Parry C. 92.  et al. 2013. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol. Biomarkers Prev. 22:561–70 [Google Scholar]
  93. Lipshultz SE, Adams MJ, Colan SD. 93.  et al. 2013. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 128:1927–55 [Google Scholar]
  94. Chow EJ, Chen Y, Kremer LC. 94.  et al. 2015. Individual prediction of heart failure among childhood cancer survivors. J. Clin. Oncol. 33:394–402 [Google Scholar]
  95. Tukenova M, Guibout C, Oberlin O. 95.  et al. 2010. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J. Clin. Oncol. 28:1308–15 [Google Scholar]
  96. Meacham LR, Chow EJ, Ness KK. 96.  et al. 2010. Cardiovascular risk factors in adult survivors of pediatric cancer—a report from the childhood cancer survivor study. Cancer Epidemiol. Biomark. Prev. 19:170–81 [Google Scholar]
  97. Armenian SH, Gelehrter SK, Vase T. 97.  et al. 2014. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. Clin. Cancer Res. 20:6314–23 [Google Scholar]
  98. Armenian SH, Xu L, Ky B. 98.  et al. 2016. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J. Clin. Oncol. 34:1122–30 [Google Scholar]
  99. Carver JR, Shapiro CL, Ng A. 99.  et al. 2007. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol. 25:3991–4008 [Google Scholar]
  100. Armstrong GT, Chen Y, Yasui Y. 100.  et al. 2016. Reduction in late mortality among 5-year survivors of childhood cancer. N. Engl. J. Med. 374:833–42 [Google Scholar]

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error